Barinthus Biotherapeutics plc - American Depositary Shares — movimiento de fondos (NASDAQ:BRNS)

Financials

Flujo de caja de las actividades operativas -32.58 M-14.43 M-50.92 M-28.94 M-47.98 M -47.98 M Flujo de caja de las actividades de inversión -12.91 M-5.75 M-5.41 M-892 K416 K 416 K Flujo de caja de las actividades financieras 222.74 M325 K1.87 M2.16 M2 000 2 000 Flujo de caja libre -33.73 M-20.57 M-56.34 M-29.83 M-48.02 M -48.02 M

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

BRNS

Financials

Barinthus Biotherapeutics plc - American Depositary Shares

Noticias

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Bio reporta datos iniciales positivos en ensayo de terapia para celiaquía

Barinthus Bio reporta datos iniciales positivos de ensayo de terapia para celiaquía

Barinthus Bio reports positive initial data from celiac therapy trial

H.C. Wainwright reitera calificación de Compra para Barinthus Biotherapeutics

Barinthus Biotherapeutics stock rating reiterated at Buy by H.C. Wainwright

Barinthus Bio and Clywedog to merge in all-stock deal

Barinthus Biotherapeutics’ CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025